This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Jazz Pharmaceuticals Ireland Limited. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: The Innovations of Ronald Cheung
Introduction
Ronald Cheung is an accomplished inventor based in Redwood City, CA (US). He has made significant contributions to the field of medicine, particularly in the treatment of hematological disorders. His innovative approach has led to the development of a unique therapeutic composition that addresses critical health issues.
Latest Patents
Ronald Cheung holds a patent for the treatment of hematological disorders. This invention relates to compositions and methods for treating patients with hematological proliferative disorders using CPX-351, a liposomal composition of daunorubicin and cytarabine, along with venetoclax. This patent showcases his commitment to advancing medical treatments and improving patient outcomes.
Career Highlights
Cheung is currently associated with Jazz Pharmaceuticals Ireland Limited, where he continues to work on groundbreaking medical innovations. His role at the company allows him to collaborate with other experts in the field and contribute to the development of new therapies.
Collaborations
Throughout his career, Ronald has worked alongside notable colleagues such as Stefan Faderl and Qi Wang. These collaborations have further enhanced his research and development efforts, leading to impactful advancements in the treatment of hematological disorders.
Conclusion
Ronald Cheung's contributions to medical innovation, particularly in hematological treatments, highlight his dedication to improving healthcare. His work exemplifies the importance of collaboration and innovation in the medical field.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
